These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 38275183)
1. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system. Xiao M; Li L; Zhu W; Wu F; Wu B Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183 [TBL] [Abstract][Full Text] [Related]
2. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. Hoffman KB; Kraus C; Dimbil M; Golomb BA PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996 [TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins. Montastruc JL Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323 [TBL] [Abstract][Full Text] [Related]
4. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600 [TBL] [Abstract][Full Text] [Related]
5. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. Akimoto H; Negishi A; Oshima S; Okita M; Numajiri S; Inoue N; Ohshima S; Kobayashi D Pharmacol Res Perspect; 2018 Dec; 6(6):e00439. PubMed ID: 30443347 [TBL] [Abstract][Full Text] [Related]
6. Effect of statins on blood pressure: Analysis on adverse events released by FDA. You T; Liu XG; Hou XD; Wang XK; Xie HH; Ding F; Yi K; Zhang P; Xie XD Clin Exp Hypertens; 2017; 39(4):325-329. PubMed ID: 28513233 [TBL] [Abstract][Full Text] [Related]
7. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS. Fujimoto M; Hosomi K; Takada M Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404 [TBL] [Abstract][Full Text] [Related]
8. Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004-2023. Liu Y; Wei C; Yuan Y; Zou D; Wu B Front Pharmacol; 2024; 15():1418498. PubMed ID: 39130635 [TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
10. Cataracts and statins. A disproportionality analysis using data from VigiBase. Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197 [TBL] [Abstract][Full Text] [Related]
11. Risk of incident diabetes among patients treated with statins: population based study. Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM BMJ; 2013 May; 346():f2610. PubMed ID: 23704171 [TBL] [Abstract][Full Text] [Related]
12. Statins and immune-mediated necrotizing myopathy: Variability in the risk. Trenque T; Hadjoudj J; Trenque A; Tralongo F; Martin S; Azzouz B Therapie; 2024; 79(3):365-370. PubMed ID: 37625939 [TBL] [Abstract][Full Text] [Related]
13. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. Dave CV; Winterstein AG; Park H; Cook RL; Hartzema AG J Affect Disord; 2018 Oct; 238():542-546. PubMed ID: 29936394 [TBL] [Abstract][Full Text] [Related]
14. Exploring the Relationship Between Atorvastatin and Memory Loss: A Comprehensive Analysis Integrating Real-World Pharmacovigilance and Mendelian Randomization. Chen K; Chen Y; Huang H Drugs R D; 2024 Jun; 24(2):317-329. PubMed ID: 38963511 [TBL] [Abstract][Full Text] [Related]
15. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study. Mueller AM; Liakoni E; Schneider C; Burkard T; Jick SS; Krähenbühl S; Meier CR; Spoendlin J J Gen Intern Med; 2021 Sep; 36(9):2639-2647. PubMed ID: 33751411 [TBL] [Abstract][Full Text] [Related]
16. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. Golomb BA; Verden A; Messner AK; Koslik HJ; Hoffman KB Drug Saf; 2018 Apr; 41(4):403-413. PubMed ID: 29427042 [TBL] [Abstract][Full Text] [Related]
18. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Trias F; Pintó X; Corbella E; Suárez-Tembra M; Ruíz-García A; Díaz-Díaz JL; Sánchez-Ruíz-Granado E; Sarasa I; Martínez-Porqueras R; Rodríguez-Sánchez MA; Corbella X; Med Clin (Barc); 2022 Jun; 158(11):531-539. PubMed ID: 34517987 [TBL] [Abstract][Full Text] [Related]
19. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745 [TBL] [Abstract][Full Text] [Related]
20. Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System. Wei C; Yin W; He Z; Wu B J Clin Med; 2023 May; 12(10):. PubMed ID: 37240654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]